# Phase 1 cancer trials recruiting: 943 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 943 trials in phase 1 for cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 cancer trials: 943 rows for $47.15, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 23 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 943
- Recruiting or not yet: 943
- Read on: November 19, 2026

## Trials

The 25 newest of 943, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07947043 | Exploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) Injection | Tongji Hospital | Phase 1 | Recruiting | Recurrent or Metastatic Lung Cancer or Cervical Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07947043) |
| November 17, 2026 | NCT07943078 | A Study of JNJ-99220732 in Participants With Advanced or Metastatic Solid Tumors | Janssen Research & Development, LLC | Phase 1 | Not yet recruiting | Neoplasms | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07943078) |
| November 17, 2026 | NCT07941531 | T-Cell Therapy Using CD7 Negative T-Cells Expressing CD7 CAR Expressed In Pediatric Patients With Hematological Malignancies. | St. Jude Children's Research Hospital | Phase 1 | Not yet recruiting | Lymphoma, AML, T-ALL, Hematologic Malignancy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941531) |
| November 17, 2026 | NCT07940881 | A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors | SystImmune Inc. | Phase 1 | Recruiting | Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, First in Human, Metastatic Solid... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940881) |
| November 17, 2026 | NCT07940738 | Ph 1 Study Long-acting Interleukin-7, Efineptakin Alfa, to Enhance Immune Reconstitution After PTCy | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 | Recruiting | Hematologic Malignancy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940738) |
| November 16, 2026 | NCT07940023 | Bispecific PSMAxCD3 Antibody CC-1 Applied Subcutaneously in Patients With Castration Resistant Prostate Carcinoma | University Hospital Tuebingen | Phase 1 | Not yet recruiting | Castration Resistant Prostate Cancer, Prostate Cancer | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940023) |
| November 10, 2026 | NCT07929961 | Study of MC001 in Patients With Advanced Solid Tumours | National University Hospital, Singapore | Phase 1 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma (PDAC), Nasopharyngeal Carcinoma, Advanced Solid Tumours | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929961) |
| November 10, 2026 | NCT07929909 | A Phase I Clinical Study of YN003 in the Treatment of Glioma | Beijing Inno Medicine Co., Ltd. | Phase 1 | Recruiting | Glioma, Glioblastoma, Brain Neoplasms | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929909) |
| November 10, 2026 | NCT07928479 | Neoadjuvant Trastuzumab, Pertuzumab and Zongertinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-5 Study | The Netherlands Cancer Institute | Phase 1 | Not yet recruiting | HER2-positive Breast Cancer, Early Breast Cancer (EBC) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928479) |
| November 10, 2026 | NCT07928258 | A Study of LY4336619 in Adult Participants With Advanced Solid Tumors | Eli Lilly and Company | Phase 1 | Not yet recruiting | Endometrial Neoplasms, Ovarian Neoplasms, Neoplasms, Germ Cell and Embryonal, Carcinoma, Non-Small-Cell Lung, Stomach... | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928258) |
| November 6, 2026 | NCT07923396 | GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis | Ruijin Hospital | Phase 1 | Not yet recruiting | Gastric Cancer (GC) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923396) |
| November 6, 2026 | NCT07923214 | A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors | Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumors, Breast Cancer, Ovarian Cancer, Gastric Cancer, Other Solid Tumors | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923214) |
| November 6, 2026 | NCT07923071 | A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment | Syndax Pharmaceuticals | Phase 1 | Not yet recruiting | Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923071) |
| November 5, 2026 | NCT07919509 | A Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During... | University of Alabama at Birmingham | Phase 1 | Not yet recruiting | Cancer, Chemotherapy, Squamous Cell Carcinoma (SCC) | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919509) |
| November 4, 2026 | NCT07915297 | Safety and Biodistribution of \[68Ga\]Ga DOTA-5G in Subjects With Metastatic Breast Cancer (BC) | Luminance Biosciences Inc | Phase 1 | Not yet recruiting | Metastatic Breast Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915297) |
| November 2, 2026 | NCT07911293 | Intratumoral Chlorine Dioxide Injection in Advanced Solid Tumors | SunGlow Innovations LLC | Phase 1 | Not yet recruiting | Solid Tumor, Neoplasms | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911293) |
| November 2, 2026 | NCT07910942 | A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer | Kanvas Biosciences | Phase 1 | Not yet recruiting | Non-Small Cell Lung Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910942) |
| November 2, 2026 | NCT07909356 | A Study of MC001 in Patients With Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) and Other Folate Receptor Alpha... | Medicovestor, Inc | Phase 1 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor Cancer, Metastatic Pancreatic Cancer, Metastatic Solid... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909356) |
| October 30, 2026 | NCT07906691 | A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Pancreatic Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906691) |
| October 29, 2026 | NCT07905677 | Phase 1 Study of VT-101 in Advanced Ovarian Cancer | Sponsor not shown (see the record) | Phase 1 | Recruiting | Epithelial Ovarian Cancer, Ovarian Cancer | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905677) |
| October 29, 2026 | NCT07905001 | A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer | Prelude Therapeutics Incorporated | Phase 1 | Recruiting | Breast Cancer, Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, HR-positive Breast Cancer... | 242 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905001) |
| October 29, 2026 | NCT07903857 | SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors | Guizhou Sinorda Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Colorectal Neoplasms, Stomach Neoplasms, Solid Tumor Malignancies | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903857) |
| October 29, 2026 | NCT07903415 | A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors. | Pfizer | Phase 1 | Recruiting | Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma... | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903415) |
| October 28, 2026 | NCT07901959 | Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia | Rockefeller University | Phase 1 | Recruiting | Fanconi Anemia, Head and Neck Cancer, Squamous Cell Carcinoma, Squamous Cell Cancer of Head and Neck (SCCHN) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901959) |
| October 28, 2026 | NCT07899892 | A Study of 68Ga-FAPI Breast PET/MRI Scans in People With Breast Cancer | Memorial Sloan Kettering Cancer Center | Phase 1 | Recruiting | Breast Cancer, Invasive Breast Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899892) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 27 |
| National Cancer Institute (NCI) | 25 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 19 |
| West China Hospital | 15 |
| Memorial Sloan Kettering Cancer Center | 15 |
| City of Hope Medical Center | 14 |
| Washington University School of Medicine | 10 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 10 |
| UNC Lineberger Comprehensive Cancer Center | 9 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 8 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 7 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 7 |
| H. Lee Moffitt Cancer Center and Research Institute | 7 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 7 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 7 |
| Second Affiliated Hospital of Guangzhou Medical University | 7 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 7 |
| Baylor College of Medicine | 6 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 6 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 5 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 5 |
| St. Jude Children's Research Hospital | 5 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 5 |
| Sichuan University | 5 |
| [Astellas Pharma Global Development, Inc.](https://specstream.ai/data/clinical-trials/company/astellas-pharma-global-development-inc) | 5 |

## By country

| Country | Trials |
| --- | --- |
| United States | 561 |
| China | 244 |
| Spain | 77 |
| Australia | 74 |
| France | 60 |
| Canada | 53 |
| South Korea | 48 |
| United Kingdom | 45 |
| Japan | 40 |
| Italy | 27 |
| Netherlands | 24 |
| Germany | 22 |
| Israel | 21 |
| Denmark | 17 |
| Taiwan | 16 |
| Belgium | 16 |
| Puerto Rico | 8 |
| Switzerland | 7 |
| New Zealand | 5 |
| Poland | 5 |
| Brazil | 5 |
| Georgia | 5 |
| Singapore | 5 |
| Portugal | 4 |
| Sweden | 4 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pediatric neurology practices in the United States](https://specstream.ai/data/businesses/pediatric-neurology-practices/united-states)
- [Mills in the United States](https://specstream.ai/data/businesses/mills/united-states)
- [Korean restaurants in the United States](https://specstream.ai/data/businesses/korean-restaurants/united-states)
- [Home staging companies in the United States](https://specstream.ai/data/businesses/home-staging-companies/united-states)
- [Flight schools in the United States](https://specstream.ai/data/businesses/flight-schools/united-states)
- [Education services in the United States](https://specstream.ai/data/businesses/education-services/united-states)
